A new daily weight loss pill could offer an alternative to GLP-1 injections in the UK. Here’s how the so-called Mounjaro pill differs.
A new weight loss pill could give UK patients something the recent boom in GLP-1 treatment has conspicuously lacked: the option to leave the needle out of it.
Orforglipron, sold under the brand name Foundayo, is a once-daily tablet approved in the UK for weight management and type 2 diabetes, with private availability expected in the coming weeks.
Predictably, it has already acquired a catchier name: the “Mounjaro pill”.
It is a useful nickname in much the same way that calling every vacuum cleaner a Hoover is useful. Everyone knows roughly what you mean. It is not, however, medically accurate.
Mounjaro contains tirzepatide and is taken as a weekly injection. Foundayo contains orforglipron and is taken daily by mouth. They sit in the same broad GLP-1 conversation but are different medicines.
And that distinction matters.
Why the new weight loss pill could appeal to people avoiding injections
The attention surrounding injectable weight-loss treatments can make the injection itself sound like a minor technicality.
For plenty of people, it isn’t.
Some simply dislike needles. Others experience considerably stronger anxiety about them. And administering an injection to yourself is a different proposition from tolerating one occasionally at the doctor’s surgery.
Pharmacist Sobia Qasim, of UK online pharmacy Curely, says that barrier can determine whether somebody considers treatment at all.
“For some people, the biggest barrier to considering weight-loss medication isn’t necessarily the treatment itself. It’s the fact that it involves injecting themselves.
Having an oral option could make GLP-1 treatment feel much more accessible to people who are uncomfortable with needles or simply prefer taking medication as a tablet.
That doesn’t mean a tablet will automatically be better than an injection. What is exciting is that patients could have greater choice, and that gives prescribers another option when looking at what treatment fits someone’s circumstances and lifestyle.”
That last qualification is important. Removing the injection does not automatically turn a tablet into the better treatment.
It does remove one obvious objection.
For somebody who has already decided that self-injection is a line they would rather not cross, that is hardly a trivial change.
Daily pill or weekly jab? Convenience cuts both ways
The obvious attraction of a tablet is familiarity. Swallow it with the rest of your medication and get on with the day.
Except daily medication also has to be remembered daily.
Mounjaro’s weekly injection asks patients to deal with their treatment less frequently, while the new oral option creates a daily routine. Which sounds easier depends rather heavily on whose diary you are holding.
Qasim explains: “Convenience means different things to different people. Someone who already takes daily medication may find adding another tablet to that routine incredibly straightforward. Someone else might prefer having to think about their treatment only once a week.
This is why having different options is useful. Successful treatment isn’t only about what works in a clinical trial. Patients also need to be able to realistically incorporate it into their lives.”
This is perhaps the least glamorous part of the weight-loss drug debate and one of the more sensible.
Medication has to survive contact with ordinary life: work, mornings, holidays, forgotten alarms and that peculiar human ability to remember something every day until the precise day it matters.
Is the ‘Mounjaro pill’ actually Mounjaro in tablet form?
No.
The nickname is likely to prove difficult to dislodge because Mounjaro has become such a recognisable reference point for injectable weight-loss medication. But patients should not mistake convenient shorthand for pharmaceutical equivalence.
Mounjaro contains tirzepatide. The new daily tablet contains orforglipron.
Qasim says: “Calling it the ‘Mounjaro pill’ is an easy way of explaining why the launch is attracting so much attention, but medically they’re different treatments.
The important development for patients is choice. We are moving towards a situation where weight-management treatment isn’t synonymous with having an injection.
For some people an injectable treatment may remain the most appropriate option. For others, an oral treatment may fit their circumstances better. Those decisions should always be made with an appropriate prescriber rather than based purely on which format sounds more convenient.”
So the more useful comparison is not simply pill good, needle bad.
Treatment suitability also depends on someone’s medical history, other medication and the advice of an appropriate prescriber. Preference matters. It just doesn’t get the casting vote.
A weight loss pill may also make travelling simpler
There is another practical attraction to tablets: luggage.
Travelling with medication already involves keeping track of packaging, storage guidance and changes to routine. Adding injection equipment can create another layer of organisation that some patients would happily avoid.
A tablet may therefore feel less cumbersome or more discreet while travelling.
That does not mean it should be treated like a packet of mints thrown into a washbag five minutes before the taxi arrives. Patients are advised to keep medication in its original packaging and check the relevant storage instructions before travelling.
The format may be simpler. The medication is still medication.
Are weight-loss injections about to disappear?
Hardly.
It is tempting to frame every new treatment as the executioner of whatever came before it. Tablets replace injections; streaming kills television; metal woods bury persimmon. Reality usually has room for more than one thing at once.
The significant development here is choice.
Someone comfortable with injections may prefer a treatment they only need to think about weekly. Someone already taking tablets every morning may find a daily oral treatment far easier to accommodate. Someone with serious needle anxiety could view the difference rather more emphatically.
That is why the arrival of an oral GLP-1 is potentially important without needing to declare the death of the injection pen.
As Qasim puts it: “The biggest story here isn’t that tablets are replacing injections. It’s that patients are gaining another option.
We’ve seen an enormous change in weight-management treatment over the past few years, and the arrival of an oral GLP-1 is another important step. For people who have previously been put off treatment because of injections, it could make the conversation around their options very different.”
The weekly jab, then, need not start clearing its desk.
But for the first time, the needle may no longer be the price of admission.
